Cipla: Jefferies on Cipla Maintains Underperform with Target Price of ₹1,120 as it sees only ~12% upside even in a blue-sky scenario, remains bearish versus its bullish view on Mankind, and believes Cipla’s bull case relies on timely approval of two US drugs, which it considers unlikely.

 09 Jul 2026 08:58 AM

Cipla: Jefferies on Cipla Maintains Underperform with Target Price of ₹1,120 as it sees only ~12% upside even in a blue-sky scenario, remains bearish versus its bullish view on Mankind, and believes Cipla’s bull case relies on timely approval of two US drugs, which it considers unlikely.

Cipla: Co to Consider Q1 Results on July 23

 01 Jul 2026 02:16 PM

Cipla: Co to Consider Q1 Results on July 23

Cipla: Co. Grows Manufacturing for Respiratory and Specialty Products in India, China, and the U.S. - BS

 17 Jun 2026 09:03 AM

Cipla: Co. Grows Manufacturing for Respiratory and Specialty Products in India, China, and the U.S. - BS

Cipla Ltd: Appoints Mr. Shivam Puri As New CEO, Formerly At Hindustan Unilever, Jubilant Foodworks, And ITC.

 16 Jun 2026 01:11 PM

Cipla Ltd: Appoints Mr. Shivam Puri As New CEO, Formerly At Hindustan Unilever, Jubilant Foodworks, And ITC.

Cipla: USFDA Labels CIPLA's Goa Facility Inspection As Voluntary Action Indicated With Observations, No Immediate Action Required.

 11 Jun 2026 01:56 PM

Cipla: USFDA Labels CIPLA's Goa Facility Inspection As Voluntary Action Indicated With Observations, No Immediate Action Required.

Cipla: Says Most Of Its Main Revenue Will Be From Generic Drugs. - CNBC TV18

 10 Jun 2026 03:18 PM

Cipla: Says Most Of Its Main Revenue Will Be From Generic Drugs. - CNBC TV18

Cipla: Aims To Achieve 10% Of Total Revenue From Innovations In The Next Five Years. - CNBCTV18

 10 Jun 2026 03:18 PM

Cipla: Aims To Achieve 10% Of Total Revenue From Innovations In The Next Five Years. - CNBCTV18

Cipla: Co Aims To Create More Innovations That Are Relevant Worldwide - CNBC TV18

 10 Jun 2026 03:19 PM

Cipla: Co Aims To Create More Innovations That Are Relevant Worldwide - CNBC TV18

Cipla: Citi maintains a Buy on Cipla with a raised Target Price of ₹1700, citing robust yet realistic FY27 growth outlook driven by ~15% India business growth, resilient US sales despite gRevlimid and Lanreotide phase-outs, management’s $1 billion FY27 US exit run-rate guidance, achievable FY27 EBITDA margin guidance of 18.5–20%, and potential for FY28 EBITDA margins to exceed 21% if pipeline execution stays on track.

 14 May 2026 09:00 AM

Cipla: Citi maintains a Buy on Cipla with a raised Target Price of ₹1700, citing robust yet realistic FY27 growth outlook driven by ~15% India business growth, resilient US sales despite gRevlimid and Lanreotide phase-outs, management’s $1 billion FY27 US exit run-rate guidance, achievable FY27 EBITDA margin guidance of 18.5–20%, and potential for FY28 EBITDA margins to exceed 21% if pipeline execution stays on track.

Cipla: Co Expects To Achieve A Us$1 Billion Run Rate For Its North America Business By The End Of Fy27, Driven By New Product Launches, With A Significant Ramp-up Anticipated In The Second Half Of The Year. This Guidance Excludes Any Contribution From Lanreotide. - Concall Update

 14 May 2026 09:01 AM

Cipla: Co Expects To Achieve A Us$1 Billion Run Rate For Its North America Business By The End Of Fy27, Driven By New Product Launches, With A Significant Ramp-up Anticipated In The Second Half Of The Year. This Guidance Excludes Any Contribution From Lanreotide. - Concall Update

Cipla: Gross Margins Are Anticipated To Have A Positive Bias Due To The Higher Margin Profile Of In-house Respiratory Products, A Shift Towards Chronic Therapies In India, And Ongoing Cost Control Initiatives, Despite Potential Temporary Impacts From Geopolitical Situations. - Concall Update

 14 May 2026 09:01 AM

Cipla: Gross Margins Are Anticipated To Have A Positive Bias Due To The Higher Margin Profile Of In-house Respiratory Products, A Shift Towards Chronic Therapies In India, And Ongoing Cost Control Initiatives, Despite Potential Temporary Impacts From Geopolitical Situations. - Concall Update

Cipla: For The One India Business, Management Is Confident In Delivering Strong Double-digit Growth And Outperforming The Market In Fy27-28, Building On Consistent Trends Observed In Recent Quarters. - Concall Update

 14 May 2026 09:01 AM

Cipla: For The One India Business, Management Is Confident In Delivering Strong Double-digit Growth And Outperforming The Market In Fy27-28, Building On Consistent Trends Observed In Recent Quarters. - Concall Update

Cipla: The Company Projects EBITDA Margins For Fy27 To Be In The Range Of 18.5% To 20%, With Sequential Improvement Expected, Primarily In The Second Half Of The Year, And This Guidance Does Not Include Any Contribution From Lanreotide. - Concall Update

 14 May 2026 09:01 AM

Cipla: The Company Projects EBITDA Margins For Fy27 To Be In The Range Of 18.5% To 20%, With Sequential Improvement Expected, Primarily In The Second Half Of The Year, And This Guidance Does Not Include Any Contribution From Lanreotide. - Concall Update

Cipla: Citi maintains a Buy on Cipla with a raised Target Price of ₹1700, citing strong Q4 trends led by 15% India growth, resilient US sales despite gRevlimid/Lanreotide phase-out, gross margin expansion, positive FY27 outlook with a $1 billion US sales run-rate target and strong pipeline visibility, while management remains confident of sustaining 18.5–20% EBITDA margins in FY27 and 20%+ in FY28 despite input cost pressures.

 14 May 2026 08:58 AM

Cipla: Citi maintains a Buy on Cipla with a raised Target Price of ₹1700, citing strong Q4 trends led by 15% India growth, resilient US sales despite gRevlimid/Lanreotide phase-out, gross margin expansion, positive FY27 outlook with a $1 billion US sales run-rate target and strong pipeline visibility, while management remains confident of sustaining 18.5–20% EBITDA margins in FY27 and 20%+ in FY28 despite input cost pressures.

Cipla: HSBC maintains a Hold on Cipla with a Target Price of ₹1340, citing a Q4FY26 miss and FY27 EBITDA margin guidance of 18.5–20% factoring no resolution in Lanreotide supplies, while execution of upcoming launches remains crucial for achieving the targeted $1 billion annualized US sales run-rate, with further US sales progress key to sustaining growth.

 14 May 2026 08:58 AM

Cipla: HSBC maintains a Hold on Cipla with a Target Price of ₹1340, citing a Q4FY26 miss and FY27 EBITDA margin guidance of 18.5–20% factoring no resolution in Lanreotide supplies, while execution of upcoming launches remains crucial for achieving the targeted $1 billion annualized US sales run-rate, with further US sales progress key to sustaining growth.

Cipla: JPM upgrades Cipla to Overweight with a Target Price of ₹1550, citing improved earnings visibility from a strong US launch pipeline including gVentolin, gAdvair, gSymbicort and peptides, management’s FY27 US revenue run-rate guidance of $1 billion, and attractive valuations after the recent correction with the stock trading at a discount to peers like Dr. Reddy’s and Lupin.

 14 May 2026 08:57 AM

Cipla: JPM upgrades Cipla to Overweight with a Target Price of ₹1550, citing improved earnings visibility from a strong US launch pipeline including gVentolin, gAdvair, gSymbicort and peptides, management’s FY27 US revenue run-rate guidance of $1 billion, and attractive valuations after the recent correction with the stock trading at a discount to peers like Dr. Reddy’s and Lupin.

CIPLA: CO EXEC SAYS - AS IRAN CRISIS PROLONGS, SOME COST ESCALATIONS START SEEPING INTO SYSTEM || SO FAR, WE HAVE CUSHIONED IMPACTS OF FREIGHT AND SUPPLIES INTO THE MIDDLE EAST REGION THROUGH INVENTORY

 13 May 2026 03:30 PM

CIPLA: CO EXEC SAYS - AS IRAN CRISIS PROLONGS, SOME COST ESCALATIONS START SEEPING INTO SYSTEM || SO FAR, WE HAVE CUSHIONED IMPACTS OF FREIGHT AND SUPPLIES INTO THE MIDDLE EAST REGION THROUGH INVENTORY

Cipla: Co Exec Says - Have Been Facing Challenges In Front Of Freight And Supplies Into The Middle East Region

 13 May 2026 03:28 PM

Cipla: Co Exec Says - Have Been Facing Challenges In Front Of Freight And Supplies Into The Middle East Region

CIPLA: U.S. SALES AT $155M VS $167M (QOQ)

 13 May 2026 01:04 PM

CIPLA: U.S. SALES AT $155M VS $167M (QOQ)

Cipla: Company Plans North America Respiratory Pipeline - 5 Assets Filed (4 Assets Anticipated to Launch in FY 27), 4 Assets Expected to Be Filed in Next 24 Months, 2 Assets to Be Filed with Green Propellant Soon

 13 May 2026 01:07 PM

Cipla: Company Plans North America Respiratory Pipeline - 5 Assets Filed (4 Assets Anticipated to Launch in FY 27), 4 Assets Expected to Be Filed in Next 24 Months, 2 Assets to Be Filed with Green Propellant Soon